TCM
SAGE

Tekla Capital Management’s Sage Therapeutics SAGE Stock Holding History

Tekla Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-82,800
Closed -$3.5M – 154
2015
Q3 		$3.5M Buy
+82,800
New +$5.1M 0.13% 118

Other funds holding SAGE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Tekla Capital Management's SAGE Position: Q3 2021 in Review

Tekla Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2021, closing a stake of 114,119 shares — an estimated $6.48M sold.

Tekla Capital Management first reported a position in SAGE in Q3 2014 and held it in 27 quarters. The position peaked at $22.5M in Q2 2018. 225 funds tracked by Wall St. Rank hold SAGE as of Q3 2021.

  • Tekla Capital Management reported no remaining Sage Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Tekla Capital Management sold 114,119 Sage Therapeutics shares in Q3 2021, an estimated $6.48M.
  • Tekla Capital Management first reported a position in Sage Therapeutics in Q3 2014 and held it in 27 quarters.
  • Tekla Capital Management's Sage Therapeutics position peaked at $22.5M in Q2 2018.
  • 225 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2021.

Based on Tekla Capital Management's 13F filing for Q3 2021, filed 12 Nov 2021.